Evaluate the Diagnostic and Prognostic Significance of ANA, CRP, and ESR In RA Patients

Authors

  • Sikna Ali Salman Department of Biochemistry, College of Medicine, University of Tikrit,Salah Al-deen, Iraq
  • Nihad Nejres Hilal Department of Biochemistry, College of Medicine, University of Tikrit,Salah Al-deen, Iraq
  • Mohammed M.Abdul-Aziz Department of Surgery, College of Medicine, University of Tikrit, Salah Al-deen, Iraq

DOI:

https://doi.org/10.32792/jmed.2025.29.3

Keywords:

Rheumatoid Arthritis, ANA, CRP, ESR

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease marked by systemic
inflammation and joint damage. CRP and ESR are commonly used to assess
disease activity, while ANA is frequently detected in autoimmune diseases,
though its role in RA remains debated. To assess the relationship of ANA, CRP,
and ESR with disease activity in RA patients and evaluate their diagnostic and
prognostic value. A case-control study was conducted at Marjan Teaching
Hospital and Al-Mahaweel General Hospital with 90 participants: 60 RA
patients (25 males, 35 females) and 30 healthy controls (15 males, 15 females),
aged 20–55. ANA and CRP were measured using ELISA, and ESR was
analyzed using standard methods. Statistical tests included Mann-Whitney U,
Spearman’s correlation, and ROC curve analysis. patients had significantly
elevated CRP and ESR levels compared to controls (p < 0.001). ANA was
positive in 35% of patients and was linked to more severe symptoms. CRP and
ESR showed a strong correlation (r = 0.79, p < 0.001), while ANA had a
moderate correlation with disease severity (r = 0.45, p < 0.05). CRP and ESR
had good diagnostic accuracy (AUC = 0.905 and 0.832), while ANA was less
useful diagnostically.CRP and ESR are reliable indicators of inflammation and
disease activity in RA. While ANA is not a key diagnostic marker, it may
suggest more severe disease when present. These markers can aid in clinical
assessment and management.

References

-Symolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. Doi:10.1016/S0140

(16)30173-8.

-Chen L, Wu B, Mo L, Chen H, Zhao Y, Tan T, et al. Associations between biological ageing and the risk of, genetic

susceptibility to, and life expectancy associated with rheumatoid arthritis: A secondary analysis of two observational

studies. Lancet Healthy Longev. 2024;5:e45–e55. Doi:10.1016/S2666-7568(23)00220-9

- Chen L, Wu B, Mo L, Chen H, Zhao Y, Tan T, et al. Associations between biological ageing and the risk of, genetic

susceptibility to, and life expectancy associated with rheumatoid arthritis: A secondary analysis of two observational

studies. Lancet Healthy Longev. 2024;5:e45–e55. doi:10.1016/S2666-7568(23)00252-

-Bossuyt X, De Langhe E, Borghi MOMeroni PL. Understanding and interpreting antinuclear antibody tests in

systemic rheumatic diseases. Nat Rev Rheumatol. (2020) 16:715–26. doi: 10.1038/s41584-020-00522-wPubMed

Abstract | CrossRef Full Text | Google Scholar

-Stochmal A, Czuwara J, Trojanowska MRudnicka L. Antinuclear antibodies in systemic sclerosis: an update. Clin

Rev Allergy Immunol. (2020) 58:40–51. doi: 10.1007/s12016-018-8718-8PubMed Abstract | CrossRef Full Text |

Google Scholar

-Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against

Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum

Dis. (2019) 78:1151–9. doi: 10.1002/art.40930PubMed Abstract | CrossRef Full Text | Google Scholar

-Aletaha, Daniel, and Josef S Smolen. “Diagnosis and Management of Rheumatoid Arthritis: A Review.” JAMA vol.

-Shapiro SC. Biomarkers in Rheumatoid Arthritis. Cureus. 2021 May 16;13(5):e15063. doi: 10.7759/cureus.15063.

PMID: 34141507; PMCID: PMC8205440.

-Liu F, Wang XQ, Zou JW, Li M, Pan CC, Si YQ. Association between serum antinuclear antibody and rheumatoid

arthritis. Front Immunol. 2024 Apr 22;15:1358114. doi: 10.3389/fimmu.2024.1358114. PMID: 38711518; PMCID:

PMC11070521.

-Bossuyt, Xavier et al. “Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.”

Nature reviews. Rheumatology vol. 16,12 (2020): 715-726. doi:10.1038/s41584-020-00522-w

-Stochmal, Anna et al. “Antinuclear Antibodies in Systemic Sclerosis: an Update.” Clinical reviews in allergy &

immunology vol. 58,1 (2020): 40-51. doi:10.1007/s12016-018-8718-8

Downloads

Published

2025-06-25